
[PRESS RELEASE] – FORT LAUDERDALE, Fla., Feb. 24, 2025 – Bright Green Corp. announced that on Feb. 24, 2025, on behalf of the company, Lynn Stockwell asked the court to approve the restructuring security agreement (RSA). The highlights of the RSA will provide new equity for the company to pay all creditors with approved claims in full; in addition, the company equity shareholders will retain their interests in the company and are unimpaired with no dilution.
The company in its restructuring efforts entered into an agreement with the Drug Enforcement Administration (DEA) to immediately withdraw all cannabis-related renewal applications. This agreement will allow for reinstatement once the company has satisfied that there is commercial value, and the federal government clarifies a path that will stabilize operations for medical research and possible drug development.
Stockwell, the new CEO and chairperson of the company’s board of directors, also sponsors and manages other public corporations that are building a financial war chest to be used for acquisitions of revenue-generating, well-managed corporations for the platform of onshoring controlled substance production, API and manufacturing back to the U.S.
“The company will not canvas equity and then jeopardize shareholder value by the uncertainty of the United States cannabis industry; currently this is not a business where normal banking is prohibited,” Stockwell said. “I have reset the course for Bright Green to become the first mover in the production of legal controlled substances for medical purpose establishing a reliable API supply chain”
These legal controlled substances have never been produced commercially in the United States. The critical supply is imported from countries where diversion and quality controls are not a priority.
“This new federal administration is actively positioning Bright Green to participate in the production, drug manufacturing and prescription drug delivery back to the United States,” Stockwell said. “This creates an opportunity for Bright Green where the drugs purchased in the United States has a total addressable market of hundreds of billions of dollars. With likely tariffs protecting this new American industry and supply contracts, the company will move forward to implement its planned owner/operator operations for a $3.5 billion investment. The owner/operators will implement this capital to build new DEA and FDA-compliant mega-farms for the production facilities to produce controlled substances that can supply quality API by contract for the MADE IN AMERICA supply chain.
“Each American farmer owner/operator will have access to federal loan guarantees to support the new infrastructure that is expected to create thousands of new jobs for the infrastructure construction while fostering the company’s EB-5 program with investment through legal immigration for this new business. The company will continue its exclusive partnership with Asia Capital Pioneer Group Inc. to help support its EB-5 marketing efforts across Asia and the world.”
Gurvinder Singh will rejoin the company as general manager responsible for the EB-5 program administered by Bright Green Regional Center LLC and help direct the company forward.
The company’s planned revenue is from contracts for the production of controlled substances and EB-5 investment, the $800,000 investment from applicants seeking a green card administered by the USCIS EB-5 program that could generate significant capital from qualified applicants who seek entry into the United States through legal immigration.
The company believes that the timing for both revenue streams will create this opportunity and Bright Green Corp. will reset in a very positive way immediately.